Mesh Bio, a Singapore-based health deep tech startup in transforming chronic disease management through predictive analytics, announced that it had raised an undisclosed amount of funding from East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia. The funding will be allocated to further develop the digital twin technologies in chronic disease management and to expand its services across Southeast Asia, mainly Indonesia, Malaysia, and the Philippines.